Background Responsiveness to erythropoiesis-stimulating agents (ESAs) has been reported
to be associated with increased cardiovascular disease (CVD) and mortality in patients …

Anemia is a frequent and early chronic kidney disease (CKD) complication. Its management
is currently based on oral or intravenous iron supplements, erythropoiesis-stimulating …

Anemia is a common complication of chronic kidney disease (CKD) and is associated with a
decrease in quality of life and an increased risk of transfusions, morbidity and mortality, and …

Erythropoiesis-stimulating agents (ESAs) have been a common treatment for anemia
associated with chronic kidney disease (CKD), while 10–20% of patients continue to suffer …

Objective Zinc is an essential trace element, being a cofactor for almost 300 enzymes. As
zinc is widely available in the diet, the European Best Practice Guidelines do not …

Anemia is a common complication of chronic kidney disease with major option treatment of
erythropoiesis-stimulating agents (ESAs). This study aimed to investigate the influencing …

Introduction The treatment of anemia is a major activity in the care of patients undergoing
maintenance hemodialysis (HD). The comparative effectiveness of new pharmacologic …

La anemia es una complicación frecuente de la enfermedad renal crónica (ERC) y se
asocia con una disminución en la calidad de vida ya un mayor riesgo de transfusiones, de …

The sequence of involvement of factors contributed to the pathogenesis of nephrogenic
anemia (NA) begins with the development of nephrosclerosis, retention of uremic toxins and …

Introducción: La anemia es una enfermedad tan frecuente en la población general así como
en enfermedad renal crónica, tiene una incidencia mayor al 50%, lo que condiciona …